Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan, 2017–18
Open Access
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Recommendations for the use of Japanese encephalitis vaccinesPediatrics & Neonatology, 2020
- Evolving Epidemiology of Japanese Encephalitis: Implications for VaccinationCurrent Infectious Disease Reports, 2018
- Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in TaiwanVaccine, 2014
- Primary Immunization of Infants and Toddlers in Thailand with Japanese Encephalitis Chimeric Virus Vaccine in Comparison with SA14-14-2The Pediatric Infectious Disease Journal, 2014
- Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trialHuman Vaccines & Immunotherapeutics, 2012
- Estimated global incidence of Japanese encephalitis:Bulletin of the World Health Organization, 2011
- Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-oldsThe Pediatric Infectious Disease Journal, 2010
- Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trialsVaccine, 2010
- Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United StatesVaccine, 2000
- NEUROLOGICAL ASPECTS OF TROPICAL DISEASE: Japanese encephalitisJournal of Neurology, Neurosurgery & Psychiatry, 2000